Advertisement


Related Videos

Boon-Cher Goh, MD, on Cancer Drugs in Singapore: 3As (Availability, Accessibility, and Affordability)

Blase Polite, MD, MPP, FASCO, on Transforming the Drug Cost Curve in the United States: Not How But If

David T. Rubin, MD, on Biosimilars for Inflammatory Bowel Disease

Cody Peer, PhD, on Simulating Alternative Schedules for Checkpoint Inhibitors

Sarah Yim, MD, on Clinical Development of Biosimilars: Lessons for Interventional Pharmacoeconomics

Advertisement

Advertisement




Advertisement